Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627680 | PMC |
| http://dx.doi.org/10.3201/eid0501.990128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Diagnosis of Bloodstream Infections Using Serum Metabolomic Analysis.
Metabolites
December 2024
Department of Clinical Laboratory, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Background: Bloodstream infections (BSIs) pose a great challenge to treating patients, especially those with underlying diseases, such as immunodeficiency diseases. Early diagnosis helps to direct precise empirical antibiotic administration and proper clinical management. This study carried out a serum metabolomic analysis using blood specimens sampled from patients with a suspected infection whose routine culture results were later demonstrated to be positive.
View Article and Find Full Text PDFSwitch to amoxicillin-clavulanate oral therapy in urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli: Assessment by chronic phase technetium-99m dimercaptosuccinic acid renal Scintigraphy images.
J Infect Chemother
December 2024
Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.
The incidence of urinary tract infection (UTI) caused by extensive beta-lactamase-producing Escherichia coli (ESBL-EC) is increasing, including in children. However, the available oral antibiotic treatment options for ESBL-EC are limited. Herein, we report the cases of two children diagnosed with UTI caused by ESBL-EC (ESBL-UTI) who were switched from empirical intravenous antibiotics in UTI to amoxicillin-clavulanic acid (AMPC/CVA) (14:1) after the causative organism was found to be ESBL-EC.
View Article and Find Full Text PDFHigh Prevalence of Antimicrobial Resistance Genes in Multidrug-Resistant Extended-Spectrum Beta-Lactamase-Producing Clinical Isolates after COVID-19 Pandemic, North Iran.
Adv Biomed Res
October 2024
Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Background: Amid the COVID-19 pandemic, the surge in hospital admissions and widespread use of broad-spectrum antibiotics have heightened the risk of hospital-acquired infections from multidrug-resistant (MDR) organisms, particularly . It is imperative to implement stringent measures to curb the spread of antimicrobial resistance in hospitals and devise robust treatment strategies for patients grappling with such infections. To confront this challenge, a comprehensive study was undertaken to examine MDR extended-spectrum beta-lactamase (MDR-ESBL)-producing isolates from patients with nosocomial infections following the COVID-19 pandemic in Northern Iran.
View Article and Find Full Text PDFEmergence and Genetic Characterization of KLUC-3 Extended-Spectrum β-lactamase-producing Escherichia coli ST95 High-Risk Clone Causing Nosocomial Infection in Japan.
J Glob Antimicrob Resist
December 2024
Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Objectives: KLUC β-lactamase is a minor extended-spectrum β-lactamase (ESBL) derived from chromosome-encoded cefotaximase in Kluyvera cryocrescens. This study aimed to characterize the genetic context of KLUC-3-producing Escherichia coli and bla-harboring plasmids and assess nosocomial transmission.
Methods: In a national genomic surveillance conducted in 2019 and 2020, KLUC-3-producing E.
Tracing carriage, acquisition, and transmission of ESBL-producing Escherichia coli over two years in a tertiary care hospital.
Genome Med
December 2024
Laboratory of Medical Microbiology, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium.
Background: The impact of community carriage on the influx of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) into hospitals remains understudied. In this prospective 2-year single-centre study, we investigate the community ESBL-E influx and trace the colonisation, nosocomial acquisition, transmission, and infection dynamics of ESBL-producing Escherichia coli (ESBL-Ec) in non-ICU wards at a tertiary care hospital.
Methods: This study reports primary and post hoc outcomes of the clinical trial NCT01208519 in which hospitalised patients were screened for rectal carriage of ESBL-E.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!